miR-103 promotes the metastasis and EMT of hepatocellular carcinoma by directly inhibiting LATS2.

miR-103 promotes the metastasis and EMT of hepatocellular carcinoma by directly inhibiting LATS2.
复制标题

DOI:
10.3892/ijo.2018.4580
复制
发表时间:
2018-12
影响因子:
5.2
通讯作者:
Zhang SQ
Zhang SQ
中科院分区:
医学2区
文献类型:
--
作者:
Han LL;Yin XR;Zhang SQ

文献摘要

参考文献

被引文献

相似文献

由于转移和复发,提高肝细胞癌(HCC)患者的长期生存仍然是一个挑战。在本研究中,我们通过western blot分析和免疫组织化学证明,HCC细胞中miR-103的过表达促进了上皮-间质转化(EMT),并与转移增强和预后不良相关。在机制上,通过报告荧光素酶测定,我们发现丝氨酸/苏氨酸蛋白激酶,大肿瘤抑制激酶2 (LATS2), Hippo信号通路的关键组成部分,是HCC细胞中miR-103的直接靶点。Transwell实验、MTT实验和western blot分析显示,LATS2可以抵消miR-103对HCC转移、生长和EMT的功能影响。临床资料分析表明,HCC组织中miR-103的高表达与vimentin的高表达相关,而与LATS2和E-cadherin的低表达相关。miR-103也降低了yes相关蛋白(YAP)的磷酸化。综上所述,本研究结果提示miR-103通过直接抑制LATS2促进HCC转移和EMT。因此,靶向miR-103/LATS2可能被证明是一种有希望的HCC治疗策略。
Improving the long-term survival of patients with hepatocellular carcinoma (HCC) remains a challenge due to metastasis and recurrence. In this study, we demonstrate that the overexpression of miR-103 in HCC cells promotes epithelial-mesenchymal transition (EMT), and is associated with an enhanced metastasis and poor outcomes, as shown by western blot analysis and immunohistochemistry. Mechanistically, using reporter luciferase assay we reveal that the serine/threonine-protein kinase, large tumor suppressor kinase 2 (LATS2), a key component of the Hippo signaling pathway, is a direct target of miR-103 in HCC cells. Transwell assay, MTT assay and western blot analysis were performed to reveal that LATS2 can counteract the functional effects of miR-103 on HCC metastasis, growth and EMT. The analyses of clinical data indicated that a high expression of miR-103 correlated with a high expression of vimentin, but with a low expression of LATS2 and E-cadherin in HCC tissues. miR-103 also reduced yes-associated protein (YAP) phosphorylation. On the whole, the findings of this study suggest that miR-103 promotes HCC metastasis and EMT by directly inhibiting LATS2. Thus, targeting miR-103/LATS2 may prove to be a promising therapeutic strategy for HCC.
DOI: 10.1007/s10620-017-4670-3
发表时间: 2017-10-01
影响因子: 3.1
作者:
Cheng, Lina;Wang, Hongwei;Han, Shuangyin
通讯作者: Han, Shuangyin
DOI: 10.1158/0008-5472.can-12-0667
发表时间: 2012-07-15
期刊: CANCER RESEARCH
影响因子: 11.2
作者:
Chen, Hsin-Yi;Lin, Yu-Min;Chen, Ruey-Hwa
通讯作者: Chen, Ruey-Hwa
DOI: 10.1038/ncomms15773
发表时间: 2017-06-12
影响因子: 16.6
作者:
Neelakantan D;Zhou H;Oliphant MUJ;Zhang X;Simon LM;Henke DM;Shaw CA;Wu MF;Hilsenbeck SG;White LD;Lewis MT;Ford HL
通讯作者: Ford HL
DOI: 10.1007/s12094-015-1353-4
发表时间: 2016-02-01
影响因子: 3.4
作者:
Wang, S.;Li, H.;Chen, G.
通讯作者: Chen, G.
miR-92a促进肝细胞癌细胞的增殖和FOXA2靶向侵袭。
DOI: 10.22038/ijbms.2017.9010
发表时间: 2017-07
影响因子: 2.2
作者:
Wang L;Wu J;Xie C
通讯作者: Xie C